<DOC>
	<DOCNO>NCT02605213</DOCNO>
	<brief_summary>Primary sclerotic cholangitis ( PSC ) inflammatory process sclerotic cholangitis involve intra extra hepatic biliary system . There curative treatment disorder . Supportive conservative treatment common therapy use disease . Although treatment ursodeoxycholic acid ( UDCA ) recommend situation whereas hypothesis stimulatory effect intestinal anaerobic bacteria cholestridium difficile pathogenesÄ±s PSC , use antibiotic recommend treatment patient . Therefore accord great role anaerobic bacteria cholestridium difficile pathogenesis , antibiotic metronidazole vancomycin count recommended therapy PSC . In addition study correlate effect vancomycin immunomudulatory effect cause reduction inflammation biliary system . But detail finality effectiveness antibiotic therapy accordingly study investigator compare oral vancomycin effect versus placebo primary sclerosing cholangitis patient . In double blind clinical trial 30 primary sclerosing cholangitis patient divide two 15 persosns group Block Randomization method . study one group receive 250 mg oral vancomycin every 6 hour group receive placebo . The study duration 12 week . The baseline laboratory test 1 month 3 month treatment concept ; Alkaline phosphatase , ALT , AST , GGT serum total bilirubin clinical manifestation tiredness , itch probable adverse effect hypotension accompany flushing , erythematous rash face upper body ( red neck red man syndrome ) , chill drug fever , eosinophilia reversible neutropenia .</brief_summary>
	<brief_title>Effect Safety Oral Vancomycin Primary Sclerosing Cholangitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>1. primary sclerosing chollangitis diagnosis 3 month 2. inflammatory bowel disease cholestasis diagnosis 3 month 3. confirm RCPM 4. confirm pathology inflammatory bowel disease 1. sign uncompensated cirrhosis like : hepatic encephalopathy , esophageal varix bleed 2. gastrointestinal cancer hepatic cancer 3. immunosuppressive agent use hepatic problem ( vancomycine hypersensitivity )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>